All In Biotech

Drug Trial Radar · NCT07730632

Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)

A Phase II Clinical Study Evaluating the Efficacy and Safety of QLS7305 in Patients With Primary IgA Nephropathy (IgAN), C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and Primary Membranous Nephropathy (PMN)

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 10, 2026

Primary completion

Aug 10, 2028

Study completion Aug 11, 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

QLS7305 injection is a chemically synthesized double-stranded small interfering RNA (siRNA) targeting complement C3, covalently linked to a ligand containing N-acetylgalactosamine (GalNAc) residues. After subcutaneous (SC) administration, it can inhibit C3 synthesis through the RNA interference (RNAi) mechanism, reduce circulating C3 protein levels, decrease the generation of complement-activated C5 convertase, and inhibit complement pathway activation. It is expected to become an effective treatment for complement-mediated kidney diseases and hematological disorders.

Conditions

  • IgAN - IgA Nephropathy
  • Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
  • C3 Glomerulopathy (C3G)
  • Primary Membranous Nephropathy

Interventions

  • QLS7305 InjectionDrug

    Route of administration: subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the 24h-UPCR at week 12Time frame: Baseline and day 85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.